Pre-Clinical Development of a Next-Generation mRNA Vaccine for Influenza

Time: 9:00 am
day: Pre-Conference Focus Day: Respiratory Infectious Disease Vaccine Development


  • Preliminary preclinical results for second generation vaccines designed with improved anti-viral immunogenicity exhibited cross neutralization against alpha, beta, gamma and delta circulating viral variants in mice and non-human primates
  • Rhesus macaque immunogenicity studies showed high neutralizing antibody titers after two prime injections 28 days apart.
  • A further increase in neutralizing antibody titers were observed with a boost injection 120 days after the second prime injection